Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Abiomed Inc is a medical devices business based in the US. Abiomed shares (ABMD) are listed on the NASDAQ and all prices are listed in US Dollars. Abiomed employs 1,725 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $277.30 |
|---|---|
| 52-week range | $261.27 - $387.40 |
| 50-day moving average | $332.23 |
| 200-day moving average | $327.79 |
| Wall St. target price | $384.40 |
| PE ratio | 92.7295 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $3.26 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $277.3 from 2022-01-27
| 1 week (2022-01-20) | -8.41% |
|---|---|
| 1 month (2021-12-24) | N/A |
| 3 months (2021-10-27) | -19.53% |
| 6 months (2021-07-28) | -14.36% |
| 1 year (2021-01-28) | -21.92% |
|---|---|
| 2 years (2020-01-28) | 48.28% |
| 3 years (2019-01-28) | 336.9 |
| 5 years (2017-01-27) | 154.75% |
Valuing Abiomed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abiomed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Abiomed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 93x. In other words, Abiomed shares trade at around 93x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Abiomed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abiomed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Abiomed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $288.2 million.
The EBITDA is a measure of a Abiomed's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $973.6 million |
|---|---|
| Operating margin TTM | 26.92% |
| Gross profit TTM | $685.6 million |
| Return on assets TTM | 11.46% |
| Return on equity TTM | 11.62% |
| Profit margin | 15.32% |
| Book value | $30.43 |
| Market capitalisation | $13.7 billion |
TTM: trailing 12 months
We're not expecting Abiomed to pay a dividend over the next 12 months.
Abiomed's shares were split on a 2:1 basis on 1 October 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Abiomed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Abiomed shares which in turn could have impacted Abiomed's share price.
Over the last 12 months, Abiomed's shares have ranged in value from as little as $261.27 up to $387.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abiomed's is 1.2945. This would suggest that Abiomed's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2. 5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5. 0, Impella LD, and Impella 5.
Five major factors contribute to the continued bull run of Bitcoin, ARK says, including growing adoption and long-term focus of investors.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
